Population-Based Incidence and Prevalence of Systemic Lupus Erythematosus The Michigan Lupus Epidemiology and Surveillance Program

University of Michigan, Department of Obstetrics & Gynecology, Ann Arbor, MI.
Arthritis & Rheumatology (Impact Factor: 7.87). 02/2014; 66(2). DOI: 10.1002/art.38238
Source: PubMed

ABSTRACT Background: We estimated the incidence and prevalence of systemic lupus erythematosus (SLE) in a sociodemographically diverse southeastern Michigan source population of 2.4 million. Methods: SLE cases fulfilling American College of Rheumatology classification criteria (primary case definition) or rheumatologist-judged SLE (secondary definition) and residing in Wayne or Washtenaw Counties, 2002-2004 were included. Case finding was performed from 6 source types, including hospitals and private specialists. Age-standardized rates were computed, and capture-recapture performed to estimate case under-ascertainment. Results: Overall age-adjusted incidence and prevalence (ACR definition) per 100,000 were 5.5 (95% CI 5.0, 6.1) and 72.8 (95% CI 70.8, 74.8). Among females, incidence was 9.3/100,000 and prevalence was 128.7/100,000. Only 7 cases were estimated to have been missed by capture-recapture, adjustment for which did not materially impact rates. SLE prevalence was 2.3-fold higher in blacks than whites, and 10-fold higher in females than males. Among incident cases, mean age (±SD) at diagnosis was 39.3±16.6 years. Black cases had a higher proportion of renal disease and end-stage renal disease (40.5% and 15.3%) versus white cases (18.8% and 4.5%); blacks with renal disease were diagnosed with SLE at younger age [(34.4±14.9) vs whites (41.9±21.3); p=0.05]. Conclusions: SLE prevalence was higher than described in most other population-based studies, and reached 1 in 537 among black females. There were substantial racial disparities in the burden of SLE, with blacks compared to whites experiencing earlier age of diagnosis, more than 2-fold increases in SLE incidence and prevalence, and increased proportion of renal disease and progression to ESRD. © 2013 American College of Rheumatology.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: To review the association of pregnancy with the risk of subsequent development of rheumatic autoimmune diseases in women, including rheumatoid arthritis (RA), systemic lupus erythematosus, and scleroderma. There is a small but growing literature related to the risk of autoimmune rheumatic disease in association with pregnancy history. However, results conflict both in terms of the direction and magnitude of risk of disease in relationship to prior pregnancy history. Although anecdotal evidence tends to favor the premise that pregnancy is protective against certain diseases, such as RA, the heterogeneity of results precludes the ability to confirm an association in either direction. There is indication that time elapsed since pregnancy may influence risk, with the postpartum year being of particular relevance. To date, a clear pattern has not emerged regarding pregnancy and the future risk of autoimmune rheumatic diseases. This topic requires greater study, and given the strong female preponderance of these diseases, future research efforts should seek to resolve this important issue.
    Current opinion in rheumatology 03/2014; DOI:10.1097/BOR.0000000000000047 · 5.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: While ESRD from lupus nephritis (ESLN) increased in the United States after the mid-1990s and racial disparities were apparent, current trends are unknown. Retrospective US Renal Data System data (n=1,557,117) were used to calculate standardized incidence ratios (standardized to 1995-1996) and outcomes of ESLN (n=16,649). For events occurring after initiation of RRT, follow-up ended on June 30, 2011. Overall ESLN rates (95% confidence intervals [95% CIs]) in 1995-1996 were 3.1 (2.9 to 3.2) cases per million per year. Rates were higher for subgroups characterized by African-American race (11.1 [95% CI, 10.3 to 11.9]); other race (4.9 [95% CI, 4.0 to 5.8]); female sex (4.9 [95% CI, 4.6 to 5.2]); and ages 20-29 years (4.9 [95% CI, 4.4 to 5.4]), 30-44 years (4.6 [95% CI, 4.2 to 5.0]), and 45-64 years (4.0 [95% CI, 3.7 to 4.4]). Standardized incidence ratios for the overall population in subsequent biennia were 1.19 (1.14 to 1.24) in 1997-1998, 1.17 (1.12 to 1.22) in 1999-2000, 1.17 (1.12 to 1.22) in 2001-2002, 1.21 (1.16 to 1.26) in 2003-2004, 1.18 (1.13 to 1.23) in 2005-2006, 1.16 (1.11 to 1.21) in 2007-2008, and 1.05 (1.01 to 1.09) in 2009-2010, respectively. During a median (interquartile range) follow-up of 4.4 (6.3) years, 42.6% of patients with ESLN died, 45.3% were listed for renal transplant, and 28.7% underwent transplantation. Patients with ESLN were more likely than matched controls to be listed for and to undergo transplantation, and mortality rates were similar. Among patients with ESLN, African Americans were less likely to undergo transplantation (adjusted hazard ratio, 0.54 [0.51 to 0.58]) and more likely to die prematurely (adjusted hazard ratio, 1.23 [1.17 to 1.30]). While ESLN appears to have stopped increasing in the last decade, racial disparities in outcomes persist. Copyright © 2014 by the American Society of Nephrology.
    Clinical Journal of the American Society of Nephrology 12/2014; 10(2). DOI:10.2215/CJN.02350314 · 5.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We assessed the burden of systemic lupus erythematosus (SLE) among Arab and Chaldean Americans residing in southeast Michigan. For those meeting SLE criteria from the Michigan Lupus Epidemiology and Surveillance Registry, we determined Arab or Chaldean ethnicity by links with demographic data from birth certificates and with a database of Arab and Chaldean names. We compared prevalence and incidence of SLE for Arab and Chaldean Americans with estimates for non-Arab and non-Chaldean American Whites and Blacks. We classified 54 individuals with SLE as Arab and Chaldean Americans. The age-adjusted incidence and prevalence estimates for Arab and Chaldean Americans were 7.6 and 62.6 per 100 000, respectively. Arab and Chaldean Americans had a 2.1-fold excess SLE incidence compared with non-Arab and non-Chaldean American Whites. Arab and Chaldean American women had both significantly higher incidence rates (5.0-fold increase) and prevalence estimates (7.4-fold increase) than did Arab and Chaldean American men. Recognizing that Arab and Chaldean Americans experience different disease burdens from Whites is a first step toward earlier diagnosis and designing targeted interventions. Better methods of assigning ethnicity would improve research in this population. (Am J Public Health. Published online ahead of print March 19, 2015: e1-e6. doi:10.2105/AJPH.2014.302423).
    American Journal of Public Health 03/2015; 105(5):e1-e6. DOI:10.2105/AJPH.2014.302423 · 4.23 Impact Factor